Evidence map›Paper›PMID 39296272›Full record

ArticleACS pharmacology & translational science2024

Cell-Based Covalent-Capture Deubiquitinase Assay for Inhibitor Discovery.

Megan N Doleschal, Jenna Miller, Sankalp Jain, Alexey V Zakharov, Ganesha Rai, Anton Simeonov, Bolormaa Baljinnyam, Zhihao Zhuang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Megan N DoleschalDepartment of Chemistry and Biochemistry, University of Delaware, 214A Drake Hall, Newark, Delaware 19716, United States.
Jenna MillerNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States.
Sankalp JainNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States.
Alexey V ZakharovNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States.ORCID https://orcid.org/0000-0003-2466-1711
Ganesha RaiNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States.ORCID https://orcid.org/0000-0001-9763-9641
Anton SimeonovNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States.
Bolormaa BaljinnyamNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States.
Zhihao ZhuangDepartment of Chemistry and Biochemistry, University of Delaware, 214A Drake Hall, Newark, Delaware 19716, United States.ORCID https://orcid.org/0000-0001-5047-9222

Funding

This renovation project will create over 1455 sq. ft. of state- of-the-art reseaP20GM104316 · NIGMS · UNIVERSITY OF DELAWARE · PI FOX, JOSEPH M · 2014 to 2024
$26.8M
Pilot Research Subproject ProgramP30GM110758 · NIGMS · UNIVERSITY OF DELAWARE · PI POLENOVA, TATYANA · 2014 to 2018
$5.8M
Identification of small molecule inhibitors of USP15ZIATR000298 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI MARTINEZ, NATALIA · 2017 to 2025
$1.9M
NIH ADMINISTRATIVE SUPPLEMENT AUTOMATED PEPTIDE SYNTHESIZER ZHUANGR01GM129468 · NIGMS · UNIVERSITY OF DELAWARE · PI ZHUANG, ZHIHAO · 2019 to 2022
$1.3M
Developing a cell-based high throughput screening for USP15 deubiquitinase inhibitor discoveryR21NS123322 · NINDS · UNIVERSITY OF DELAWARE · PI ZHUANG, ZHIHAO · 2021 to 2021
$435k
Intramural NIH HHS ZIA TR000298NIGMS NIH HHS P20 GM104316NIGMS NIH HHS P30 GM110758NIGMS NIH HHS R01 GM129468NINDS NIH HHS R21 NS123322
6 · The paper itself

Abstract

Ubiquitination is a post-translational modification that elicits a variety of cellular responses. Deubiquitinases (DUBs) remove ubiquitin moieties from proteins and modulate cellular processes by counteracting the ubiquitin ligase activities. Ubiquitination and deubiquitination processes are tightly regulated by different mechanisms and their dysregulation is associated with many diseases. Discovery of DUB inhibitors could not only lead to therapeutics but also facilitate the understanding of ubiquitination/deubiquitination processes and their regulatory mechanisms. To enable the inhibitor discovery against DUBs, we developed a cell-based DUB assay that utilizes a cell-permeable ubiquitin probe, Biotin-cR

Identifiers

PMID39296272
PMCPMC11406687

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.